cyrilzakka/clinical-trials huggingface dataset:
Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris. Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non-invasively by venomanometry. Since phenylephrine is a vasoconstrictor, it may affect episcleral venous tone, but the effect on EVP is unknown. Understanding the physiology of episcleral veins helps us in better understanding of pathophysiology of glaucoma.


Eligibility Criteria:
Inclusion Criteria:

* Any self-declared ethno-racial category.
* Medically healthy subjects.
* Subjects with two healthy eyes.
* Intraocular pressure (IOP) less than 22 mmHg in each eye.
* Best-corrected visual acuity (BCVA) in each eye 20/50 or better.
* Open angles in both eyes.
* Contact lens wear stopped at least 3 days prior to study, and during the study.
* Ability to cooperate for examinations required for study.

Exclusion Criteria:

* Chronic or acute ophthalmic diseases including glaucoma, wet type macular degeneration, uveitis and clinically significant cataract.
* Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis.
* Cornea pathologic changes preventing reliable measurement.
* Narrow anterior chamber angle.
* Previous intraocular surgeries, laser procedures, and intravitreal injections.
* Previous corneal refractive surgeries.
* Myopia greater than -6.00 D spherical equivalent.
* Hyperopia greater than +2.00 D spherical equivalent.
* Lack of suitable episcleral vein for measurement.
* Ocular trauma within the past 6 months.
* Ocular infection or ocular inflammation in the past 3 months.
* Ocular medication of any kind within 30 days of study visit.
* Known hypersensitivity to Phenylephrine or topical anesthetic medication.
* Severe hypertension: Systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 105 mmHg.
* A known history of ischemic heart disease (angina or myocardial infarction), cerebrovascular accidents, cardiac arrhythmias, cerebral or aortic aneurysms.
* Uncontrolled diabetes mellitus.
* Uncontrolled hyperthyroidism.
* Use of some systemic medications within 30 days prior to study including: β-adrenergic antagonists, α-adrenergic agonists and antagonists, calcium channel blockers, diuretics, vasodilators, monoamine oxidase inhibitors, and systemic steroids.
* Participation in any interventional study within the past 30 days prior to study visit.
* Women who are pregnant.
Types of Photoplethysmographic Waves in Adult Patients with Septic Shock

The objective of this study is to identify the types of Photoplethysmographic waves present in adults with septic shock and determine whether these waves correlate with other variables of tissue hypoperfusion such as capillary refil, serum lactate and mottling score.

Photoplethysmography is the technology used in pulse oximeters in order to calculate arterial oxygen saturation and pulse rate, this technology generates a wave whose morphology has been related to blood flow and arterial tone. Recently Tusman and collaborators described a morphological classification of the photoplethysmografic wave that has a high correlation with arterial tone, such classification is divided in 6 types; Types I and II indicate vasoconstriction, Type III normal arterial tone and Types IV, V and VI describe mild, medium and severe vasodilation respectively, therefore it could be used to identify the arterial tone in those patients with septic shock. This study will identify the type of photoplethysmographic waves that are present in adults with septic shock based in the Tusman and collaborators classification, it will also describe the frequency of appearance and their correlation with other hemodynamic variables such as capillary refill, serum lactate, mottling score, heart rate, mean arterial pressure, pulse pressure and perfusion index.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients of 18 years of age and above dignossed with septic shock according to the definition stated in Sepsis 3.0
* Patients with axillary temperature above 36°C
* Patients and/or family that agree to participate in such study and sign the informed consentment
* Patients that tolerate supine position

Exclusion Criteria:

* Patients with Cardiogenic shock, hipovolemic, obstructive and distributive (neurogenic, anafilactic) shock the exception being septic shock
* Patients with history of any type of cardiac arrhythmia
* Patients with history of chronic hepatic disease
* Patients with limited or diffuse systemic sclerosis
* Patients that have scarring, nail polish or thickened nails that may impede the proper placement and accurate measurement of photoplethysmography with the pulse oximeter
* Patients with history of heart insufficiency P- atients with septic shock that already have vasopressor aggents
Long-term Remission After Ileorectal Anastomosis in Crohn's Disease.

Single-center, retrospective, observational study. The medical records of patients who underwent colectomy and ileorectal anastomosis (IRA) for refractory Crohn's colitis between 1996 and 2016 were reviewed.

Several studies show that, although the type of disease changes in a statistically significant way after 5 years from diagnosis, overall, a follow-up of more than 10 years indicates that the disease remains unchanged in about 85% of patients. Studies show that up to 70% of patients with Crohn's disease (CD) undergo surgery at least once in their lifetime. In colon Crohn's disease, the cumulative risk of surgery 10 years after diagnosis is lower compared to ileal Crohn's disease. For patients with extensive colitis who do not respond to medical therapy, total colectomy with ileorectal anastomosis (IRA) is a safe and effective approach. Several studies in the literature have retrospectively evaluated the recurrence rate after colectomy and IRA in Crohn's disease-related colitis, showing reasonable recurrence rates. Furthermore, several studies have highlighted that rectal involvement and the presence of perianal disease may be predictive factors for recurrence in Crohn's colitis treated with colectomy and ileorectal anastomosis (IRA). Ileal involvement in colectomy in patients with Crohn's colitis appears to be associated with a higher risk of recurrence in the small intestine and failure of the IRA. Our study is based on the hypothesis that, in patients with extensive and refractory Crohn's colitis but without rectal involvement or perianal disease, colectomy and IRA could instead drastically reduce the recurrence rate.

Eligibility Criteria:
Inclusion Criteria:

* patients with Crohn's colitis who underwent colectomy and ileorectal anastomosis

Exclusion Criteria:

* none
Urinary Catheter and Fast-track Surgery

Urinary catheter was placed during several days after colonic surgery. Nevertheless, it is probably unnecessary after Fast-Track colonic surgery. No prospective data permit to confirm it.


Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for Fast Track colonic surgery

Exclusion Criteria:

* Urinary pathology
Text Messaging Plus Motivational Interviewing in Promotion of Breastfeeding Among HIV-infected Women

The primary aim of this study is to find out whether it is feasible to conduct a larger study looking at the effect of mobile phone text messaging added to motivational interviewing on number of participants invited to the study who consented to participate and the number with complete evaluation of infant feeding practices at all study visits.

Secondary aim: In HIV-infected women initiating breastfeeding after giving birth, does interactive weekly mobile phone text messaging plus motivational interviewing versus usual care, improve self-reported adherence to exclusive or any breastfeeding 6 months post-delivery and to determine the number of women remaining in the group they were assigned until end of study or lost to follow-up (protocol adherence).

Breastfeeding reduces the risks of dying from infections and is currently recommended as the most beneficial feeding option for infants born to HIV-infected women in low-resourced settings. This recommendation contradicts previous recommendations to avoid breastfeeding to prevent mother-to-child transmission of HIV. South Africa, a high HIV prevalent country, recently phased out access to free formula milk in the public sector in support of breastfeeding for HIV-infected women. The investigators previously found that few HIV-infected South African women choose breastfeeding and among those who did, many stop breastfeeding early. This study involves text messaging breastfeeding advice encouraging women to exclusively breastfeed, and inquire if they have any breastfeeding related problems, and motivational interviews exploring and supporting woman's commitment to continue breastfeeding.Participants meeting inclusion criteria who consent participation will be enrolled by a research nurse and immediately randomly assigned to text messaging plus motivational interviewing group or usual standard of care group.

The investigators propose a randomized, parallel group, standard of care-controlled pilot trial which will be conducted among HIV-infected women of low socio-economic background, giving birth at a primary healthcare clinic in Cape Town, South Africa. The pilot trial will assess the feasibility of conducting a larger trial on communication and support approaches that may improve HIV-infected woman's adherence to exclusive and continued breastfeeding.

Eligibility Criteria:
Inclusion Criteria:

* Women living with HIV
* initiated breastfeeding within 24 hours of giving normal birth
* on ART
* 18 years or older
* ownership of a mobile phone
* infants judged to be in good health who are discharged soon after delivery

Exclusion Criteria:

* initiating both breastfeeding and formula feeding or formula feeding within 24 hours of giving birth.
* gave birth to more than one infant
* birth weight \< 2500
* gestational age \< 36 weeks
Evaluation Conducted to Capture Patients With Diabetic Retinopathy in General Practitioners, Using SW as Medical Device

A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using AI medical device

A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using the SWaMD medical device and the SWaMD comparator, when evaluating the patients retinal image

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged ≥ 40 years
* Signed informed consent
* Confirmed type 1 or 2 diabetes mellitus

Exclusion Criteria:

* Ocular findings that do not allow retinal photography (significant nystagmus, corneal leukoma, dense cataract, hemophthalmus, etc.)
* Patient has a condition or is in a situation that, in the opinion of the investigator, may bias the results of the study, may significantly interfere with the patient's participation in the investigation, or may result in unproducible photographs of a dilated ocular fundus
* Patients with restrictions on personal freedom by administrative or legal order
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE

MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).

Chronic central serous chorioretinopathy (CSCR) is characterized by persistent subretinal fluid (SRF) and extensive outer retinal damage on optical coherence tomography (OCT). In the last years several treatment modalities for chronic CSCR have been investigated. These treatments have included pharmacologic therapy, photodynamic therapy (PDT) and microsecond laser.

PDT is the main treatment for CSCR, especially for chronic CSCR. But the efficacy of PDT is variable and could be associated with various complications such as retinal pigment epithelium (RPE) atrophy. Furthermore other limitations of PDT are unavailability and high cost.

Recently some studies have suggested an efficacy of micropulse laser in chronic CSCR, with stabilization of visual acuity, improvement in retinal sensitivity and without any complications.

The present study aims to evaluate the efficacy of a treatment by guided micropulse laser in the management of chronic CSCR. The efficacity will be evaluated 6 weeks and 3 months after the treatment on anatomical outcomes (central macular thickness in microns)

Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* vision complaints for more than 6 weeks
* subretinal fluid confirmed on OCT
* diagnosis of CSCR confirmed by fluorescein and indocyanine green angiography
* Signed informed consent
* Affiliated or beneficiary of health insurance

Exclusion Criteria:

* History of treatment of CSC with other modalities (PDT, eplerenone) in the past 3 months
* Other macular conditions : Age-related Macular Degeneration (AMD), polypoidal vasculopathy, choroidal neovascularization
* Cataract or opacities interfering with acquisition or treatment
* Myopia\> 6 diopter
* Visual acuity\<20/200
* Treatment with steroids (per-os, inhaled or cutaneous) in the past 3 months
* Intra-vitreal injections of anti-VEGF (Vascular Endothelial Growth Factor) or steroids in the past 3 months
* History of allergy to fluorescein or indocyanine
* Inability to agree to participate to the study
* Pregnant or breastfeeding woman
* Patient under legal protection
Gait and Balance of Diabetes Type 2 Patients

Type 2 diabetes is one of the fastest growing public health problems in both developed and developing countries. It is estimated that the number of people with diabetes in the world will double in coming years, from 171 million in 2000 to 366 million in 2030.The role of physiotherapy in diabetic care is to reduce immobilisation effects, to maintain functional capacity and to minimise diabetes-related complications. The physiotherapist also has a role in providing advice about exercise and daily living activities. The fundamental principle of rehabilitation is to improve quality of life while diminishing the health care burden. By reducing the heightened risk of falling, the fall related injuries and the fear of falling one could improve quality of life in diabetic patients and reduce health care costs.

The goal of this study is to investigate the effectiveness of gait and balance training in pre frail subgroup diabetes patients. Our program is based on recommendations of Robertson et al.(2002) and Page et al.(2002) The investigators randomly assign patients in a control group (no treatment) or in a treatment group. The treatment program consists of two group sessions per week over 12 weeks. Patients were encouraged to perform specific home exercises. After this 12-week program, patients were asked to continue their exercises. The effect of the treatment will be evaluated after the treatment program and after a 6-month follow up.


Eligibility Criteria:
Inclusion Criteria:

* Past or present patient from the University Hospital in Geneva
* Diagnosed with diabetes by the medical doctor (glycaemia \> 7 mmol on two different tests on an empty stomach)
* Presence of a peripheral neuropathy (vibration perception ≤ 4)

Exclusion Criteria:

* Patients with a foot ulcer at the moment of intake
* Patients with orthopaedic or chirurgical problems influencing gait parameters
* Patients with a non diabetic neuropathy (Charcot, alcohol, Thyroid dysfunction)
* Patients with neurological problems influencing gait parameters
* Patients with incapacity to walk without a walking aid
Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions

The purpose of this study is to evaluate the effect of FFR (Fractional flow reserve) guided Percutaneous Coronary Intervention in coronary tandem lesions.


Eligibility Criteria:
Inclusion Criteria:

* Tandem lesion evaluated by FFR
* Written consent

Exclusion Criteria:

* TIMI flow \< 3
* Grafted vessel
* Left ventricular ejection fraction \< 30%
* Severe calcification and/or severe tortuosity
* Uncontrolled coronary spasm
* Life expectancy \< 2 years
* Planned high risk surgery
* Pregnancy or breast-feeding
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.


Eligibility Criteria:
Inclusion Criteria:

1. Adult renal transplant recipients, men and women between 18 and 75 years of age.
2. Any patient with acute graft dysfunction (elevation of creatinine above post transplant nadir)

   AND, two out of three, of the following Inclusion Criteria:
3. Presence of circulating anti human leukocyte antigen (HLA) antibody (DSA "donor specific antibody").
4. Histological findings compatible with Banff Class II or III AMR on transplant biopsy.
5. Peritubular capillary c4d positivity on transplant biopsy.

Exclusion Criteria:

1. Patients that have received eculizumab prior to enrolling in the study.
2. Patients with ongoing non-acute antibody mediated rejection.
3. Patients with predominantly chronic antibody mediated rejection or interstitial fibrosis/tubular atrophy.
4. History of severe cardiac disease (e.g., New York Heart Association \[NYHA\] Functional Class III or IV, myocardial infarction ≤ 6 months of randomization, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases)
5. Prior splenectomy
6. Has a known bleeding disorder
7. Has any active bacterial or other infection which is clinically significant in the opinion of the Investigator and is a contraindication to transplantation
8. Has participated in any other investigational drug study or was exposed to an investigational drug or device within 30 days of screening
9. Has received rituximab (Rituxan®) ≤ 3 months prior to screening
10. Has received bortezomib (Velcade®) ≤ 3 months prior to screening
11. Has received alemtuzumab (Campath®) ≤ 6 months prior to screening
12. Need for concurrent treatment with anti thymocyte globulin (Thymoglobulin®)
13. Hypersensitivity to murine proteins or to one of the product excipients
14. History of illicit drug use or alcohol abuse within the previous year
15. Unresolved meningococcal disease
16. Pregnancy or lactation
17. Current cancer or a history of cancer within the 5 years prior to screening with the exception of patients who have successfully treated non-metastatic basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; or breast carcinoma in situ
18. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient Active infection with Hepatitis B (HBV), Hepatitis C (HCV) or human immunodeficiency virus (HIV)
Young Women on Sexual and Reproductive Health Knowledge and Stigma Levels

Aim: Failure to exercise reproductive and sexual rights can increase the risk of unwanted pregnancies, HIV and sexually transmitted infections, sexual coercion and violence, especially in young women. All of these situations affect the physical and mental health of young girls, as well as the health of their families.For this reason, The Effect of Education Given to Young Women on Sexual and Reproductive Health Knowledge and Stigma Levels: A Randomized Controlled Study was planned.

Material and method: The research was conducted as a randomized controlled experimental study. The universe of the research consisted of female students studying at the Faculty of Health Sciences of Ağrı İbrahim Çeçen University between January and June 2022. The sample consisted of individuals who were studying at the Faculty of Health Sciences of Ağrı İbrahim Çeçen University between the same dates and who met the inclusion criteria of the research. "Descriptive Feature Form", "Sexual and Reproductive Health Stigma Scale for Young Women" and sexual health knowledge test were used to collect data. In the analysis of data; percentile distribution, chi-square, Fisher-Freeman- Halton Exact test, paired samples test, t-test in independent groups, Friedman Test, One Way ANOVA test, and post hoc analyzes (Bonferroni, Games Howell, Dunn) were used.


Eligibility Criteria:
Inclusion Criteria: Be between the ages of 18-24. Agree to participate voluntarily. -

Exclusion Criteria: be over 24 years old

-
MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs

Radiotherapy to the breast and lymph nodes is routinely planned using CT scans. The introduction of magnetic resonance imaging (MRI) has the potential to better visualise the lymph nodes and so define a smaller treatment area or 'target'. This means that the dose delivered to the target could be increased without increasing the dose to normal tissues. The MIRABELLE study is designed to test if this is possible by recruiting patients diagnosed with breast cancer including lymph node disease. The investigators will ask participants to have a CT scan and an MRI scan before they have radiotherapy. The investigators will then plan radiotherapy using both these scans and compare the possible dose delivered to the lymph nodes using the MRI and CT defined lymph nodes. This will not affect the patient's future treatment.

MR imaging has the potential to improve both the localisation of pan-LN treatments and the subsequent treatment delivery using MR-linac technology. The MIRABELLE study will apply the MR sequences developed in LN-negative volunteers/patients to the context of node-positive breast cancer patients with the aim of reducing the delineated nodal volume thereby facilitating dose-escalation to involved LNs. The benefit of using MRI for LN localisation as compared to conventional CT imaging will be investigated by determining whether a higher dose can be delivered using MRI- as compared to CT-based delineation. Any increase in dose will be deemed a success as this has potential to improve tumour control. In addition, inter-observer errors in outlining will be explored to investigate whether these are reduced using MRI. Reduced inter-observer errors would result in smaller margins for error such that less normal tissue could be irradiated.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Female or male
* Invasive carcinoma of the breast (left or right-sided)
* cT1-T4,N3,M0-1 disease
* Due to proceed to primary treatment (chemo, surgery, radiotherapy and/or endocrine therapy)
* Histopathological involvement of axillary lymph nodes confirmed on FNA or Bx
* Likely to undergo locoregional radiotherapy as part of their breast cancer management

Exclusion Criteria:

* Implanted pacemakers and/or pacing wires
* Cochlear implants
* Programmable hydrocephalus shunts
* Implanted neurostimulation systems
* Implanted drug infusion pumps
* Ferromagnetic implants
* Claustrophobia